ABSTRACT
ABSTRACT Purpose To describe the speech of a patient with Pierre Robin Sequence (PRS) and severe speech disorders before and after participating in an Intensive Speech Therapy Program (ISTP). Methods The ISTP consisted of two daily sessions of therapy over a 36-week period, resulting in a total of 360 therapy sessions. The sessions included the phases of establishment, generalization, and maintenance. A combination of strategies, such as modified contrast therapy and speech sound perception training, were used to elicit adequate place of articulation. The ISTP addressed correction of place of production of oral consonants and maximization of movement of the pharyngeal walls with a speech bulb reduction program. Therapy targets were addressed at the phonetic level with a gradual increase in the complexity of the productions hierarchically (e.g., syllables, words, phrases, conversation) while simultaneously addressing the velopharyngeal hypodynamism with speech bulb reductions. Results Re-evaluation after the ISTP revealed normal speech resonance and articulation with the speech bulb. Nasoendoscopic assessment indicated consistent velopharyngeal closure for all oral sounds with the speech bulb in place. Conclusion Intensive speech therapy, combined with the use of the speech bulb, yielded positive outcomes in the rehabilitation of a clinical case with severe speech disorders associated with velopharyngeal dysfunction in Pierre Robin Sequence.
Subject(s)
Humans , Male , Child , Speech Therapy/methods , Velopharyngeal Insufficiency/physiopathology , Pierre Robin Syndrome/diagnostic imaging , Velopharyngeal Insufficiency/therapy , Cleft Palate , EndoscopyABSTRACT
Para el 2015 >50% de la población con infección por el virus de inmunodeficiencia humana será >50 años, proponiéndose diversos retos en su atención. En el presente estudio se planteó como objetivo evaluar la respuesta a la terapia antirretroviral altamente activa, características epidemiológicas y clínicas en pacientes con infección del virus de inmunodeficiencia humana/síndrome de inmunodeficiencia adquiridad >50 años. Se realizó estudio descriptivo, retrospectivo, observacional, no experimental, con diseño de casos y controles (pacientes >50 años, casos; y <50 años, controles), comparando sus evaluaciones basales, a los 6 y a los 12 meses, entre enero 2005 y junio 2009. Se incluyeron 311 pacientes, 99 casos (>50 años) y 121 controles (<50 años), representado el género femenino un tercio de la población. Más del 65% consultaron en etapas avanzadas de la enfermedad, 47% correspondieron con síndrome de inmunodeficiencia adquirida estadio C3. La medida del lapso entre diagnóstico e inicio de la terapia antirretroviral altamente activa fue >1 año, en los grupos. Los regímenes de terapia antirretroviral altamente activa más usados fueron AZT/3TC/EFV y AZT/3TC+LOP/RIT. No se encontraron diferencias significativas en la respuesta inmunológica ni virológica a la terapia antirretroviral altamente activa a los 6 y 12 meses entre los grupos; valores promedio de carga viral a los 6 meses: 58221,08 copias de ARN/mm³ (2,21 log) y 6081,92 copias de ARN/mm³ (2,28 log) para adultos mayores y jóvenes, respectivamente. En adultos mayores , el incremeto de valores promedio de linfocitos TCD4+pos-terapia antirretroviral altamente activa fue significativa (P<0,05) comparando niveles basales y a los 12 meses; en los jóvenes dicha significancia se alcanzó a los 6 meses. Más del 85% de los pacientes tuvieron carga viral indetectable por 12 meses. En los pacientes >50 años se observó buena respuesta inmunológica y virológica similar a los jóvenes, a los 6 y 12 meses de la terapia....
For the year 2015 >50% of the population living with the human immunodeficiency virus infection will be >50 years old, facing it diverse challenges in their attention. In the current study the objetive to assess the response to the highly active antiretroviral therapy (HAART), epidemiological and clinical characteristics in patients with human immnodeficiency virus infection/acquired immunodeficiency syndrome >50 years old, was proposed. A descriptive, retrospective, observational, non-experimental, cases and control desing study (patients >50 years old, cases; and <50 years old, controls), comparing their basal, at 6 months and t 12 months evalutions, between january 2005 and june 2009, was done. A total 311 patients, 99 cases (>50 years old) and 212 controls (<50 years old) were included. Females represented a third of the population. More than 65% of the patients consulted in advanced stages of diseases, 47% corresponded with acquired immnodeficiency syndrome stage C3. Mean time between diagnosis and beginning of highly active antiretroviral therapy was >1 year, in both groups. Most used highly active antiretroviral therapy schemes were AZT/3TC/EFV and AZT/3TC+LOP/RIT. No significant differences between immunological and virological responce to highly active antiretroviral therapy at 6 and 12 months between both groups were found; mean values of viral load at 6 months: 5,821.08 RNA copies/mm³ (2.21 log) and 6,081.92 RNA copies/mm³ (2.28 log) for mayor adults and young patients, respectively. In mayor adults, increase in mean values of TCD4 + lymphocyte counts post-highly active antiretroviral therapy were significant (P<0.05) when compared basal with 12 months moments. In young patients that significant change was reached at 6 months. More than 85% of the patients had undetectable viral at 12 months. In patients >50 years old a good immunological and virological responce was observed, being similar to that seen in young patients, at 6 and 12 months.....
Subject(s)
Humans , Male , Female , Middle Aged , HIV , Acquired Immunodeficiency Syndrome/therapy , Antiretroviral Therapy, Highly Active/methods , Virology/methodsABSTRACT
La leishmaniosis tegumentaria americana (LTA) como enfermedad endémica crónica continúa afectando a la población del medio rural venezolano, ocasionándole morbilidad y limitaciones laborales. Mediantes la descripción de casos clínicos se evaluaron 38 pacientes con LTA que recibieron atención hospitalaria por úlceras leishmánica en miembros inferiores. De los pacientes descriptos 63% eran niños, 84% procedía del Estado Miranda, 66% tenía una lesión ulcerosa única, 45% recibió cefadroxilo previo al tratamiento antiparasitario específico y el 24% había recibio inmunoterapia previa para la enfermedad. Treinta y siete pacientes (97%) recibieron antimoniato de meglumina en series terapéuticas de aiez días y uno anfoterecina B, por contraindicación cardiovascular para el uso del antimonial. Todos presentaron re-epitelización adecuada de sus lesiones, por lo que el antimoniato de meglumina demuestra una vez más su utilidad en la terapéutica de esta zoonosis parasitaria.
American tequmentary leishmaniasis (ATL) endemic chronic disease continues to affect the population of rural Venezuela, causing morbidity and labor constraints. By the description of clinical were evaluated 38 patients with ATL who received hospital care for leishmanial ulcers in lower limbs. Sixty-three percent of the patients were children, 84% came from Miranda state, 66% had a unique ulcerated lesion, 45% received cefadroxil prior to parasite specific treatment and 24% had received immunotherapy for the diseaes. Thirtyseven patients (97%) received meglumine antimoniate in series of ten days and one patient received anfotericine B, due to cardiovascular contraindication for the use of the antimonial. All ulcers healed. The antimoniate of meglumine demonstrates once again its usefulness in the treatment of this parasitic zoonosis.